Business Context and Reporting Period
Company: Retractable Technologies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Overview: The Company designs, develops, manufactures, and markets safety syringes and other safety medical products. Primary products include the VanishPoint insulin syringe and Patient Safe syringe. Manufacturing occurs in Little Elm, Texas, and via a contract manufacturer in China (Double Dove).
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Net Sales | $5,258,465 | $5,315,155 |
| Gross Profit | $1,229,176 | $1,285,731 |
| Gross Margin | 23.4% | 24.2% |
| Net Loss | $(3,907,641) | $(2,863,595) |
| Loss Per Share (Basic & Diluted) | $(0.18) | $(0.13) |
| Cash and Cash Equivalents | $28,652,448 | $39,209,597 (End of Q1 2008) |
| Working Capital | $26,264,652 | $33,376,806 (End of Q1 2008) |
| Total Debt (Current + Long-term) | $7,700,513 | N/A |
| Current Ratio | 3.0 | 4.3 (Dec 31, 2008) |
Note: Working Capital calculated as Total Current Assets ($39,083,359) minus Total Current Liabilities ($12,818,707).
Material Changes vs. Prior Period
- Revenue: Net sales decreased slightly by 1.1% ($57,690) compared to Q1 2008. Domestic sales declined 9.7% due to lower volumes, while international sales increased 54.0% driven by higher volumes and prices.
- Profitability: Net loss increased by 36.5% to $3.91 million. The increase in loss was primarily driven by a 20.8% rise in operating expenses, specifically General and Administrative costs due to litigation expenses.
- Cash Flow: Net cash used by operating activities increased significantly to $3.07 million (from $1.07 million in Q1 2008). Investing activities consumed $1.43 million, primarily for the purchase of property, plant, and equipment related to warehouse expansion.
- Balance Sheet: Cash balances decreased by $4.63 million during the quarter. Inventory increased by $1.12 million, with raw materials rising to secure supply chains and finished goods increasing to support production ramp-up.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Liquidity: Management states it has sufficient cash reserves from prior litigation settlements and does not intend to raise equity capital. Operations, cash reserves, and debt financing are the primary funding sources.
- Market Access: The Company continues to face barriers to hospital market access due to monopolistic practices by competitor Becton Dickinson (BD). Strategies include litigation, international expansion, and new product introductions.
- Cost Management: The Company is focusing on upgrading manufacturing efficiency and shifting piece part manufacturing in-house to reduce costs. A $0.005 per unit price increase from Chinese manufacturer Double Dove in late 2008 may impact margins.
- Royalties: Expected royalty payments from a licensing agreement with BTMD (China) have not yet commenced due to infrastructure and regulatory delays, though the facility is complete.
Risks and Contingencies:
- Litigation: Significant ongoing legal proceedings include a breach of contract suit against Abbott Laboratories (trial set for Jan 2010) and multiple patent infringement suits against BD, OMI, and SMI. Litigation costs are a major expense driver.
- Supplier Concentration: Approximately 72.1% of finished products in Q1 2009 were sourced from Double Dove in China. Disruption here would require a costly shift to domestic production for specific syringe types.
- Customer Concentration: Two significant customers accounted for 28.6% of net sales in Q1 2009.
- Preferred Stock Dividends: The Company has significant cumulative dividends in arrears on five series of Class B Preferred Stock, totaling over $14 million in total arrearage as of March 31, 2009.
Investor Verification Checklist
- Litigation Status: Verify the current status and potential financial impact of the lawsuits against Abbott, BD, OMI, and SMI, as these drive significant G&A expenses and future revenue potential.
- Supplier Dependency: Assess the risk associated with relying on Double Dove for 72.1% of production and the feasibility/cost of shifting to domestic manufacturing if supply is disrupted.
- Preferred Stock Arrears: Review the total accumulated dividends in arrears ($14M+) and the implications for common shareholders regarding future distributions or conversions.
- BTMD Royalties: Monitor the timeline for the commencement of royalty payments from the Chinese licensee, BTMD, which is a key anticipated revenue stream.
- Debt Refinancing: Confirm the refinancing of the $4.2 million construction loan for the warehouse expansion, which is expected in Q2 2009.